New mechanisms of action of irreversible monoamine oxidase type B inhibitors.
X M
XM
Li
A V
AV
Juorio
I A
IA
Paterson
A A
AA
Boulton
D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002493:Central Nervous System Diseases / Q000188:drug therapy; D004298:Dopamine / Q000378:metabolism; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D007980:Levodopa / Q000378:metabolism / Q000627:therapeutic use; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000627:therapeutic use*
D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline; D007980:Levodopa; D004298:Dopamine